These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 27444658)

  • 61. Current standards and new innovative approaches for treatment of pancreatic cancer.
    Conroy T; Bachet JB; Ayav A; Huguet F; Lambert A; Caramella C; Maréchal R; Van Laethem JL; Ducreux M
    Eur J Cancer; 2016 Apr; 57():10-22. PubMed ID: 26851397
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The Oncological Stress Test of Neoadjuvant Therapy: A Systematic Review in Outcomes of Neoadjuvant Therapy Compared to Upfront Resection Approach for Borderline Resectable Pancreatic Adenocarcinoma.
    Ross SB; Popover J; Sucandy I; Christodoulou M; Pattilachan TM; Rosemurgy AS
    Am Surg; 2024 Nov; 90(11):3061-3073. PubMed ID: 38635295
    [TBL] [Abstract][Full Text] [Related]  

  • 63. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
    Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
    Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.
    Greer SE; Pipas JM; Sutton JE; Zaki BI; Tsapakos M; Colacchio TA; Gibson JJ; Wiener DC; Ripple GH; Barth RJ
    J Am Coll Surg; 2008 Mar; 206(3):451-7. PubMed ID: 18308215
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer.
    Libbey N; Gallagher L; Cantalino J; Weinberg BA; Noel MS; He AR; Radkani P; Marshall JL; Weiner LM; Jackson PG; Fishbein TM; Winslow ER; Haddad N; Rashid A; Unger KR
    J Gastrointest Cancer; 2024 Jun; 55(2):852-861. PubMed ID: 38347342
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment.
    Takahashi S; Kinoshita T; Konishi M; Gotohda N; Kato Y; Kinoshita T; Kobayashi T; Mitsunaga S; Nakachi K; Ikeda M
    J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):567-74. PubMed ID: 21331805
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
    Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Roy P; Scoazec JY
    Am J Clin Oncol; 2008 Dec; 31(6):545-52. PubMed ID: 19060585
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
    Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y
    World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study.
    Paniccia A; Edil BH; Schulick RD; Byers JT; Meguid C; Gajdos C; McCarter MD
    Medicine (Baltimore); 2014 Dec; 93(27):e198. PubMed ID: 25501072
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review.
    Czosnyka NM; Borgert AJ; Smith TJ
    HPB (Oxford); 2017 Oct; 19(10):927-932. PubMed ID: 28747265
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment Strategy for Borderline Resectable Pancreatic Cancer With Radiographic Artery Involvement.
    Hirono S; Kawai M; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Yamaue H
    Pancreas; 2016 Nov; 45(10):1438-1446. PubMed ID: 27088490
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.
    Kharofa J; Tsai S; Kelly T; Wood C; George B; Ritch P; Wiebe L; Christians K; Evans DB; Erickson B
    Radiother Oncol; 2014 Oct; 113(1):41-6. PubMed ID: 25443499
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Locally advanced pancreatic adenocarcinoma: reassessment of response with CT after neoadjuvant chemotherapy and radiation therapy.
    Cassinotto C; Mouries A; Lafourcade JP; Terrebonne E; Belleannée G; Blanc JF; Lapuyade B; Vendrely V; Laurent C; Chiche L; Wagner T; Sa-Cunha A; Gaye D; Trillaud H; Laurent F; Montaudon M
    Radiology; 2014 Oct; 273(1):108-16. PubMed ID: 24960211
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma.
    Lind PA; Isaksson B; Almström M; Johnsson A; Albiin N; Byström P; Permert J
    Acta Oncol; 2008; 47(3):413-20. PubMed ID: 17882555
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
    Peddi PF; Lubner S; McWilliams R; Tan BR; Picus J; Sorscher SM; Suresh R; Lockhart AC; Wang J; Menias C; Gao F; Linehan D; Wang-Gillam A
    JOP; 2012 Sep; 13(5):497-501. PubMed ID: 22964956
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.
    McClaine RJ; Lowy AM; Sussman JJ; Schmulewitz N; Grisell DL; Ahmad SA
    HPB (Oxford); 2010 Feb; 12(1):73-9. PubMed ID: 20495649
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
    Kang JH; Lee SS; Kim JH; Byun JH; Kim HJ; Yoo C; Kim KP; Ryoo BY; Kim SC
    Eur Radiol; 2021 Feb; 31(2):864-874. PubMed ID: 32813104
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Janssen QP; van Dam JL; Kivits IG; Besselink MG; van Eijck CHJ; Homs MYV; Nuyttens JJME; Qi H; van Santvoort HJ; Wei AC; de Wilde RF; Wilmink JW; van Tienhoven G; Groot Koerkamp B
    Ann Surg Oncol; 2021 Dec; 28(13):8297-8308. PubMed ID: 34142290
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
    Brada LJH; Walma MS; Daamen LA; van Roessel S; van Dam RM; de Hingh IH; Liem MLS; de Meijer VE; Patijn GA; Festen S; Stommel MWJ; Bosscha K; Polée MB; Yung Nio C; Wessels FJ; de Vries JJJ; van Lienden KP; Bruijnen RC; Los M; Mohammad NH; Wilmink HW; Busch OR; Besselink MG; Quintus Molenaar I; van Santvoort HC;
    J Surg Oncol; 2021 Sep; 124(4):589-597. PubMed ID: 34115379
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.